Adenocarcinoma, Clear Cell

• 

  Subject Areas on Research

  • A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. 
  • A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). 
  • Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer. 
  • Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. 
  • Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. 
  • Adverse health outcomes in women exposed in utero to diethylstilbestrol. 
  • An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. 
  • Analgesic medication use and risk of epithelial ovarian cancer in African American women. 
  • Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. 
  • Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. 
  • Cabozantinib in ovarian clear cell cancers: UnMET expectations. 
  • Cancer risk in women exposed to diethylstilbestrol in utero. 
  • Clear cell adenocarcinoma in a female urethral diverticulum. 
  • Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. 
  • Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. 
  • Common variants at 19p13 are associated with susceptibility to ovarian cancer. 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. 
  • Epigenetic determinants of ovarian clear cell carcinoma biology. 
  • Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. 
  • Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. 
  • High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. 
  • Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. 
  • Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus. 
  • Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. 
  • Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. 
  • Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. 
  • Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. 
  • Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma. 
  • Molecular genetics and histopathologic features of adult distal nephron tumors. 
  • Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. 
  • Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. 
  • Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. 
  • Predicting occult multifocality of renal cell carcinoma. 
  • Prenatal diethylstilbestrol exposure and cancer risk in women. 
  • Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. 
  • Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients. 
  • Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. 
  • Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. 
  • Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 
  • Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. 
  • The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. 
  • The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. 
  • The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Yan, Hai, Adjunct Professor of Pathology, Pathology